Vaccine

Available vaccines in Europe 

Vaccine composition 

On 24 September 2021WHO published recommendations for the components of influenza vaccines for use in the 2022 southern hemisphere influenza season 

Egg-based Vaccines 

  • an A/Victoria/2570/2019 (H1N1)pdm09-like virus;  

  • an A/Darwin/9/2021 (H3N2)-like virus;  

  • a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and 

  • a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus. 

Cell- or recombinant-based Vaccines 

  •  an A/Wisconsin/588/2019 (H1N1)pdm09-like virus;  

  • an A/Darwin/6/2021 (H3N2)-like virus; 

  • a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and 

  • a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus. 

  •  

It is recommended that trivalent influenza vaccines for use in the 2022 southern hemisphere influenza season contain the following: 

Egg-based vaccines  

  • an A/Victoria/2570/2019 (H1N1)pdm09-like virus;  

  • an A/Darwin/9/2021 (H3N2)-like virus; and  

  • a B/Austria/1359417/2021 (B/Victoria lineage)-like virus. 

 

Cell- or Recombinant-based vaccines  

  • an A/Wisconsin/588/2019 (H1N1)pdm09-like virus;  

  • an A/Darwin/6/2021 (H3N2)-like virus; and 

  • a B/Austria/1359417/2021 (B/Victoria lineage)-like virus 

The full report is published here 

 

On 26 February 2021, WHO published recommendations for the components of influenza vaccines for use in the 2021-2022 northern hemisphere influenza season: 

 

Egg-based Vaccines 

  • an A/Victoria/2570/2019 (H1N1)pdm09-like virus; 

  • an A/Cambodia/e0826360/2020 (H3N2)-like virus; 

  • a B/Washington/02/2019 (B/Victoria lineage)-like virus; and 

  • a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus. 

 

Cell- or recombinant-based Vaccines 

  • an A/Wisconsin/588/2019 (H1N1)pdm09-like virus; 

  • an A/Cambodia/e0826360/2020 (H3N2)-like virus; 

  • a B/Washington/02/2019 (B/Victoria lineage)-like virus; and 

  • a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus. 

 

It was recommended that the influenza B virus component of both trivalent vaccine types for use in the 2021–2022 northern hemisphere influenza season should be a B/Washington/02/2019-like virus of the B/Victoria-lineage.